Today it was reported that the CFO of Catalyst Biosciences Inc (CBIO), Payne Fletcher, exercised options to buy 1,503 CBIO shares at $4.63 a share, for a total transaction value of $6,958.
This recent transaction increases Payne Fletcher’s holding in the company by 87.03% to a total of $27.04K. In addition to Payne Fletcher, 2 other CBIO executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Catalyst Biosciences Inc has an average volume of 296.1K.
Starting in September 2018, CBIO received 6 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant.
